KRAS and neoplasm: Hence, future studies evaluating TIA with biopsy tissues before NAT intervention, refining bioinformatics pipelines in calling mutations from tumor genomic profiling with samples after NAT, or evaluating KRAS status using not only NGS but also droplet digital polymerase chain reaction, are warranted.